MP14-09 THE ROLE OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA IN NATIONAL HEALTH INSURANCE SERVICE

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I (MP14)1 Sep 2021MP14-09 THE ROLE OF CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA IN NATIONAL HEALTH INSURANCE SERVICE Joonhee Gook, Jae Hun Shim, Byung Hoon Chi, Jin Wook Kim, In Ho Chang, Tae-Hyoung Kim, Soon Chul Myung, and Se Young Choi Joonhee GookJoonhee Gook More articles by this author , Jae Hun ShimJae Hun Shim More articles by this author , Byung Hoon ChiByung Hoon Chi More articles by this author , Jin Wook KimJin Wook Kim More articles by this author , In Ho ChangIn Ho Chang More articles by this author , Tae-Hyoung KimTae-Hyoung Kim More articles by this author , Soon Chul MyungSoon Chul Myung More articles by this author , and Se Young ChoiSe Young Choi More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001995.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To compare the survival outcomes between patients with metastatic renal cell carcinoma (RCC) treated with cytoreductive nephrectomy (CN) and without CN. METHODS: We evaluated the National Health Insurance Service Database diagnosed with RCC between 2004 and 2016. We excluded other cancer before RCC diagnosis with minimum wash-out period of 2 years and no systemic therapy experience. The patients had treated with systemic therapy for metastatic RCC with or without cytoreductive nephrectomy (CN group and non-CN group). To reduce selection bias, propensity score matching (PSM) was conducted by age, sex and Charlson comorbidity index (CCI). Overall survival (OS) was compared between two groups by Kaplan-Meier method and Cox regression model in total cohort and PSM cohort. RESULTS: Among 8,962 patients with metastatic RCC, 2,695 patients underwent cytoreductive nephrectomy with systemic therapy and 6,267 patients received only systemic therapy. Non-CN group had older age (p<0.0001), more male gender (p=0.03), and higher CCI (p<0.0001), but after PSM the variables were well-matched (D<0.1). In total cohort, cytoreductive nephrectomy was a significant factor for OS (hazard ratio [HR] 0.621, 95% confidence interval [CI] 0.589-0.656, p<0.0001). In PSM cohort, cytoreductive nephrectomy was also a significant factor for OS (HR 0.807, 95% CI 0.742-0.878, p<0.0001). CONCLUSIONS: CN was performed in about 30% of metastatic RCC with systemic therapy. In appropriate surgical candidates, CN may offer a benefit for OS. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e255-e256 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Joonhee Gook More articles by this author Jae Hun Shim More articles by this author Byung Hoon Chi More articles by this author Jin Wook Kim More articles by this author In Ho Chang More articles by this author Tae-Hyoung Kim More articles by this author Soon Chul Myung More articles by this author Se Young Choi More articles by this author Expand All Advertisement Loading ...